 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||||||||||||||||||||||||||||||||
 |
Cytyc Reports That UK NHS Strategic Health Authority Will Adopt ThinPrep Pap Test as Exclusive New Cervical Screening Test
MARLBOROUGH, Mass., (Dec 14, 2004) - Cytyc Corporation, today reported that the Strategic Health Authority (SHA) of the National Health Service (NHS), covering Norfolk, Suffolk and Cambridge, United Kingdom, intends to convert all cervical screening to the ThinPrep(R) Pap Test in all eight of its laboratories. There are currently 174,000 tests processed in the Norfolk, Suffolk and Cambridge SHA each year. This exclusive arrangement represents a potential use of approximately 800,000 ThinPrep Pap Tests over the next five years. The Norfolk, Suffolk and Cambridge Strategic Health Authority's Executive Team considered the National Institute for Clinical Excellence (NICE) Guidance recommending liquid-based cytology for cervical screening and on November 15 announced that the system of choice for the SHA is the ThinPrep Pap Test. "The rationale for this decision is based on our wish to invest in a modern, highly automated system and to support the experience developed in Norfolk & Norwich University Hospital during their pilot trial" said Dr. Tony Jewell, Clinical Director and Director of Public Health for the Strategic Health Authority. "We are very proud and pleased that another large region of the UK NHS has selected the ThinPrep Pap Test for all cervical screening," said Daniel J. Levangie, Cytyc's executive vice president. "I believe our success is directly related to the proven clinical performance of our technology and the level of commitment and support provided to the NHS by the team at Cytyc UK." This decision follows similar announcements by the NHS South West, South East (East) and London Regions, as well as the decision last year by the Scottish Cervical Screening Programme to convert their cervical screening to the ThinPrep(R) System in a 5-year exclusive agreement with Cytyc UK. About HologicHologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic’s core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. Cytyc’s products cover a range of cancer and women’s health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of patients with early-stage breast cancer. Forward-Looking Statements Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to the Company's financial condition, operating results and future economic performance, and management's expectations regarding future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and proprietary technology, uncertainty of product development efforts and the success of investments in emerging technology, domestic and international product acceptance, management of growth, risks associated with litigation and arbitration, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and any healthcare reimbursement policies, and other risks detailed in the Company's filings with the Securities and Exchange Commission, included under the heading "Certain Factors Which May Affect Future Results" in its 2003 Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q filed with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in Company expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
|
||||||||||||||||||||||||||||||||||||||||
 |
 |
||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
| Home | Women's Health | R2 CAD | Suros Surgical | Skeletal Health | OEM Solutions | Customer Care Center | |||||||||||||||||||||||||||||||||||||||||
| Learning
Center | News & Events | Investor
Relations | About Hologic More Information | Locate Us | Terms of Use | Privacy Policy Copyright 2007 Hologic, Inc. All Rights Reserved. |
|||||||||||||||||||||||||||||||||||||||||